NASDAQ:FENC Fennec Pharmaceuticals (FENC) Stock Price, News & Analysis $4.57 -0.05 (-1.08%) (As of 10/7/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Fennec Pharmaceuticals Stock (NASDAQ:FENC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Fennec Pharmaceuticals alerts:Sign Up Key Stats Today's Range$4.53▼$4.6750-Day Range$4.52▼$6.4752-Week Range$4.50▼$11.92Volume93,014 shsAverage Volume116,427 shsMarket Capitalization$124.89 millionP/E Ratio152.33Dividend YieldN/APrice Target$14.00Consensus RatingBuy Company OverviewFennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Read More… 50-Yr Wall Street Legend: “Sell this AI stock NOW” (Ad)Nearly 1 million people around the world follow 50-year Wall Street veteran Marc Chaikin for his surprisingly accurate stock predictions. And in the aftermath of the biggest tech selloff since 2022...He just gave them an urgent SELL alert for one beloved AI stock. Fennec Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks40th Percentile Overall ScoreFENC MarketRank™: Fennec Pharmaceuticals scored higher than 40% of companies evaluated by MarketBeat, and ranked 725th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingFennec Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageFennec Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Fennec Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Fennec Pharmaceuticals are expected to grow in the coming year, from ($0.07) to ($0.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fennec Pharmaceuticals is 152.33, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 130.91.Price to Earnings Ratio vs. SectorThe P/E ratio of Fennec Pharmaceuticals is 152.33, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 135.55.Read more about Fennec Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.05% of the float of Fennec Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverFennec Pharmaceuticals has a short interest ratio ("days to cover") of 19, which indicates bearish sentiment.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFennec Pharmaceuticals does not currently pay a dividend.Dividend GrowthFennec Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.05% of the float of Fennec Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverFennec Pharmaceuticals has a short interest ratio ("days to cover") of 19, which indicates bearish sentiment.Change versus previous month News and Social Media1.8 / 5News Sentiment0.30 News SentimentFennec Pharmaceuticals has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Fennec Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for FENC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Fennec Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,203.00 in company stock.Percentage Held by Insiders10.98% of the stock of Fennec Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.51% of the stock of Fennec Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fennec Pharmaceuticals' insider trading history. Receive FENC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address FENC Stock News HeadlinesFennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells $12,009.14 in StockOctober 2, 2024 | insidertrades.comFennec: Operational Challenges Persist Despite Improved Financial PositionOctober 7 at 3:12 PM | seekingalpha.com[SHOCKING] Crypto Document Leak…Imagine if you could go back to 2009 and buy Bitcoin at $0.01. Or jump to 2015 and grab Ethereum at $0.75. We've created the next best thing: It's called "Crypto Revolution," and it's not just a book… it's your potential ticket to financial time travel.October 7, 2024 | Crypto 101 Media (Ad)Fennec Pharmaceuticals (NASDAQ:FENC) Stock Quotes, Forecast and News SummaryOctober 5 at 6:06 AM | benzinga.comFennec Pharmaceuticals Inc (NASDAQ:FENC) Director Rosty Raykov Sells 2,431 Shares of StockOctober 2, 2024 | americanbankingnews.comThe past three years for Fennec Pharmaceuticals (NASDAQ:FENC) investors has not been profitableOctober 1, 2024 | finance.yahoo.comFennec Pharmaceuticals to Participate in Upcoming Investor ConferencesSeptember 5, 2024 | globenewswire.comFennec Pharmaceuticals Inc (RV41.BE)August 30, 2024 | finance.yahoo.comSee More Headlines FENC Stock Analysis - Frequently Asked Questions How have FENC shares performed this year? Fennec Pharmaceuticals' stock was trading at $11.22 at the start of the year. Since then, FENC stock has decreased by 59.3% and is now trading at $4.57. View the best growth stocks for 2024 here. How were Fennec Pharmaceuticals' earnings last quarter? Fennec Pharmaceuticals Inc (NASDAQ:FENC) released its earnings results on Tuesday, August, 13th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of $0.06 by $0.26. The business had revenue of $7.26 million for the quarter, compared to analysts' expectations of $13.67 million. Fennec Pharmaceuticals had a negative trailing twelve-month return on equity of 53.38% and a net margin of 5.59%. How do I buy shares of Fennec Pharmaceuticals? Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Fennec Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD) and Trevena (TRVN). Company Calendar Last Earnings8/13/2024Today10/07/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:FENC CUSIPN/A CIK1211583 Webwww.fennecpharma.com Phone919-636-4530Fax919-890-0490EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$14.00 High Stock Price Target$15.00 Low Stock Price Target$13.00 Potential Upside/Downside+206.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$0.03 Trailing P/E Ratio152.33 Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,050,000.00 Net Margins5.59% Pretax Margin5.58% Return on Equity-53.38% Return on Assets6.14% Debt Debt-to-Equity Ratio9.86 Current Ratio8.02 Quick Ratio7.75 Sales & Book Value Annual Sales$48.89 million Price / Sales2.55 Cash FlowN/A Price / Cash FlowN/A Book Value($0.43) per share Price / Book-10.63Miscellaneous Outstanding Shares27,328,000Free Float24,327,000Market Cap$124.89 million OptionableOptionable Beta0.25 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (NASDAQ:FENC) was last updated on 10/7/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredStrikes and Economic Unrest: Are You Prepared for What’s Coming?The rapid advancement of artificial intelligence and automation is reshaping industries and posing threats to ...InvestorPlace | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredNotice: Major payout due November 19th - are you on the list?On Tuesday, November 19, 2024 smart investors will collect their share of a $1.2 billion windfall... It's p...Behind the Markets | SponsoredU.S. Stock Market Now on Verge of Collapse"Wheels Are Falling Off" The U.S. Stock Market Today, analyst Dan Ferris is back issuing a new warning. He ...Stansberry Research | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fennec Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Fennec Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.